免疫检查点
肿瘤微环境
癌症免疫疗法
免疫疗法
癌症研究
免疫系统
T细胞
封锁
癌症
癌细胞
生物
免疫学
医学
受体
内科学
作者
Julia M. DeRogatis,Karla M. Viramontes,Emily N. Neubert,Roberto Tinoco
标识
DOI:10.3389/fimmu.2021.636238
摘要
Immune checkpoint inhibition targeting T cells has shown tremendous promise in the treatment of many cancer types and are now standard therapies for patients. While standard therapies have focused on PD-1 and CTLA-4 blockade, additional immune checkpoints have shown promise in promoting anti-tumor immunity. PSGL-1, primarily known for its role in cellular migration, has also been shown to function as a negative regulator of CD4 + T cells in numerous disease settings including cancer. PSGL-1 is highly expressed on T cells and can engage numerous ligands that impact signaling pathways, which may modulate CD4 + T cell differentiation and function. PSGL-1 engagement in the tumor microenvironment may promote CD4 + T cell exhaustion pathways that favor tumor growth. Here we highlight that blocking the PSGL-1 pathway on CD4 + T cells may represent a new cancer therapy approach to eradicate tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI